Aurora Cannabis Inc (ACB)

Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹June 11, 2026 7:05 AM
PR Newswire (US) NASDAQ | TSX: ACBAchieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growthDelivers Record Annual Adjusted EBITDA1 of $53.8 million, representing 32% YoY growthCompletes Accretive Acquisition of Safari Flower Company in April, an established EU-GMP Manufacturer, adding Critical Capacity to Serve Growing Profitable International MarketsMaintains Strong Balance Sheet with ~$164.7 million of Cash, Short Term Investments and Cash Equivalents2 with no DebtEDMONTON, AB, June 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2026 periods ending March 31, 2026. "During fiscal year 2026, we exceeded our projection for global medical cannabis net revenue1 led by double-digit growth in Europe and delivered on our expectation for Adjusted EBITDA1  with both at record outcomes. Our performance validates Aurora's global medical cannabis strategy which has positioned us as a leading provider in Canada, Europe, Australia, and New Zealand," said Executive Chairman and Chief Executive Officer for Aurora, Miguel Martin."We believe Aurora's leadership in medical cannabis is built upon our regulatory expertise, extensive and recently expanded supply network of EU-GMP certified facilities, and proven commercial execution. We are confident that these attributes create a competitive advantage as we navigate the evolving industry dynamics to maintain and expand global market share, while driving international growth," concluded Mr. Martin.[1] This news release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures.[2] Cash Equivalents refers to cash, restricted cash and cash equivalents.Fourth Quarter 2026 Highlights(Unless otherwise stated, comparisons are made between fiscal Q4 2026 and Q4 2025 results and are in Canadian dollars and reflects only the results of continuing operations, unless otherwise noted. On February 17, 2026, the Company completed the divestiture of its 50.1% ownership interest in Bevo Agtech Inc. ("Bevo"). As such, Bevo has been excluded from the Company's Q4 2026 continuing results, along with comparative figures, due to its classification as a discontinued operation.)Consolidated Revenue and Adjusted Gross Profit:    
Total net revenue1 was $84.8 million, as compared to $76.8 million in the prior year period. The 10% increase from the prior year period was mainly due to 14% growth in our global medical cannabis business and higher wholesale bulk cannabis net revenue, offset by lower quarterly net revenue1 in our consumer cannabis business.Consolidated adjusted gross margin before fair value adjustments1 was 60% in Q4 2026 and 65% in the prior year period. Adjusted gross profit before FV adjustments1 was $50.5 million in Q4 2026 compared to $50.2 million in the prior year period.Medical Cannabis:
Medical cannabis net revenue1 was $77.1 million, a 14% increase from the prior year period, delivering 91% of Aurora's Q4 2026 consolidated net revenue1 and 101% of adjusted gross profit before fair value adjustments1.The increase in medical cannabis net revenue1 of $9.3 million was primarily due to higher sales in Germany, related to increased market size, and growth in Poland, along with higher revenue in Canada to insured patients related to broader portfolio offerings.Adjusted gross margin before fair value adjustments1 on medical cannabis net revenue1 was 66% for the three months ended March 31, 2026, compared to 71% in the prior year period. The year-over-year decrease was due to higher sales with lower margins and strategic price reductions.Consumer Cannabis:
Aurora's consumer cannabis net revenue1 was $3.6 million, compared to $8.2 million in the prior year period. The decrease was due to our strategic shift to focus on Canadian and international medical cannabis and wind down our consumer business.Adjusted gross margin before fair value adjustments1 on consumer cannabis net revenue1 was 22%, a decrease from 27% compared to the prior year period. The decrease is primarily due to higher input costs related to third-party sourcing.Adjusted Selling, General and Administrative ("Adjusted SG&A"):
Adjusted SG&A1 was $40.3 million for the three months ended March 31, 2026, compared to $35.4 million in the prior year period. The increase compared to the prior year period relates to increased headcount, higher contract labour in Europe and Australia, an expected credit loss of $1.9 million due to the insolvency of two customers and additional professional fees relating to public company costs incurred in the fourth quarter of the fiscal year.Net Income (Loss):
Net loss from continuing operations for the three months ended March 31, 2026 was $27.6 million compared to a net loss of $12.1 million for the prior year period. The increase in net loss from continuing operations of  $15.4 million was primarily related to other expenses of $1.7 million in the current period, compared to other income of $11.9 million in the prior year period. This was slightly offset by an increase in gross profit of $2.5 million.Adjusted Net Income:
Adjusted net income1 was $5.6 million for the three months ended March 31, 2026 compared to $15.3 million for the prior year period. The $9.7 million decrease primarily relates to an increase in adjusted SG&A of $4.9 million, a decrease in foreign exchange gains and interest income, of $10.3 million and $4.5 million, respectively.Adjusted EBITDA:
Adjusted EBITDA1 was $9.2 million for the three months ended March 31, 2026 compared to $14.1 million for the prior year period.Free Cash Flow:
Free cash flow was $0.3 million compared to $5.2 million in the prior year quarter. Free cash flow decreased by $4.9 million primarily due to a decrease in gross profit before fair value adjustments of  $5.3 million.Strategic Business UpdatePlant Propagation:
On February 3, 2026, Aurora and its wholly owned subsidiary entered into a definitive agreement with Bevo Agtech Inc and Bevo Farms Ltd. pursuant to which, among other things, Aurora agreed to exchange all of its common shares of Bevo for preferred shares of Bevo. On February 17, 2026, the transaction closed, resulting in the disposal of the Company's 50.1% ownership interest in Bevo and loss of control. The financial results of Bevo are no longer consolidated in Aurora's financial statements subsequent to the closing of the transaction. Safari Flower Company Acquisition:
On April 15, 2026, the Company acquired Safari Flower Company ("Safari"), through a share purchase acquisition, for total consideration of $26.5 million, subject to customary closing adjustments. The consideration is composed of $15 million in cash and 2,417,180 Common Shares with an approximate fair value of $11.5 million. Included in the total consideration is contingent consideration totaling $2 million upon satisfying certain GMP certifications.The acquisition of Safari provides the Company with a 59,000 square foot EU-GMP certified indoor cultivation and manufacturing facility to supply cannabis to key international markets while reducing reliance on third party purchases.Fiscal Full Year 2027 Outlook:
Our outlook reflects the strategic changes we have made in exiting our low margin Canadian Consumer and Plant Propagation businesses, which will allow the Company to reallocate resources to focus on global medical cannabis. We believe this is our highest return opportunity to create value.Over the next few quarters, we are purposely investing in our international business through strategic sales initiatives and EU GMP capacity expansion to support growth in our most profitable markets. These efforts are expected to help offset the impact of margin reductions in our Canadian medical business, following the reduction in government reimbursed pricing, effective April 1, 2026.Total Net Revenue1 is expected to decline and be more in line with our Cannabis Net Revenue results in fiscal year 2025, following the changes in Canadian medical partially offset by international growth, driven by Germany and Poland.Adjusted Gross Margin before FV adjustments1 are expected to be in the mid to high fifties, driven by higher revenue contributions from Europe and the exit from the lower margin businesses. These benefits will partially offset lower margins in Canadian Medical.Adjusted SG&A1 is expected to remain broadly in line with the prior fiscal year.Adjusted EBITDA1 is expected to vary quarter over quarter, leading to lower annual adjusted EBITDA1 compared to the prior fiscal year. This change in expectations is due to the revisions in reimbursed pricing that drive lower net revenue and adjusted gross profits contributions.Key Quarterly Financial Results($ thousands)Three months endedMarch 31, 2026December 31, 2025$ Change% ChangeMarch 31, 2025$ Change% ChangeFinancial Results(3)






Net revenue (1)84,81682,8931,9232 %76,7688,04810 %Medical cannabis net revenue (1)77,09676,2478491 %67,7769,32014 %Consumer cannabis net revenue (1)3,6455,160(1,515)(29 %)8,166(4,521)(55 %)Adjusted gross margin before FV adjustments on
     total cannabis net revenue(1)60 %66 %N/A(6 %)65 %N/A(5 %)Adjusted gross margin before FV adjustments on medical
     cannabis net revenue(1)66 %69 %N/A(3 %)71 %N/A(5 %)Adjusted gross margin before FV adjustments on
     consumer cannabis net revenue(1)22 %28 %N/A(6 %)27 %N/A(5 %)Adjusted SG&A expense(1)40,25434,8675,38715 %35,4034,85114 %Adjusted EBITDA (1)9,22718,371(9,144)(50 %)14,056(4,829)(34 %)Adjusted net income (1)5,58111,711(6,130)(52 %)15,272(9,691)(63 %)Free cash flow (1)31618,569(18,253)(98 %)5,249(4,933)(94 %)







Balance Sheet






Working capital (1)330,523299,90130,62210 %367,465(36,942)(10 %)Cannabis inventory and biological assets (2)169,629191,064(21,435)(11 %)193,980(24,351)(13 %)Total assets601,087775,292(174,205)(22 %)852,666(251,579)(30 %)







(1)These terms are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.(2)Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies and consumables.(3)Results shown are from continuing operations. On February 17, 2026, the Company completed the divestiture of its 50.1% ownership interest in Bevo. As such, Bevo has been excluded from the Company's Q4 2026 continuing results, along with comparative figures, due to its classification as a discontinued operation.Conference CallAurora will host a conference call today, Thursday, June 11, 2026, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session will follow management's presentation.DATE:Thursday, June 11, 2026TIME:8:00 a.m. Eastern Time | 6:00 a.m. Mountain TimeWEBCAST:Click Here

About Aurora Cannabis Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking StatementsThis news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's fiscal 2026 results; statements under the heading "Fiscal Full Year 2027 Outlook ", including, but not limited to, those related to expectations for net revenue, adjusted gross margin before FV adjustments, adjusted EBITDA, and adjusted SG&A; statements regarding the Company's long-term outlook, ability to respond to changing global market dynamics and ability to mitigate the impact of margin reductions in the Canadian medical business; statements regarding the Company's global medical cannabis leadership and anticipated growth in the Company's international medical business; and statements regarding the Company's conference call to discuss results.These forward-looking statements are only predictions. Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things,  assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crisis ,and other risks as set out under the heading "Risk Factors" in the Company's annual information form dated June 11, 2026 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com  and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.Non-GAAP MeasuresThis news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the FY26 Q4 MD&A is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the U.S. Securities and Exchange Commission's (the "SEC") EDGAR website at www.sec.gov.Net Revenue, Adjusted Gross Profit and MarginNet revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:($ thousands)Three months endedYears endedMarch 31, 2026December 31, 2025March 31, 2025March 31, 2026March 31, 2025Medical cannabis net revenue(1)




Canadian medical cannabis net revenue28,31428,25026,751112,116107,432International medical cannabis net revenue48,78247,99741,025176,524137,010Total medical cannabis net revenue(1)77,09676,24767,776288,640244,442





Consumer cannabis net revenue(1)3,6455,1608,16623,54840,033





Wholesale bulk cannabis net revenue(1)4,0751,4868268,4054,436





Total net revenue(1)84,81682,89376,768320,593288,911(1)These terms are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.Adjusted EBITDAThe following is the Company's adjusted EBITDA:($ thousands)Three months endedYears endedMarch 31, 2026December 31, 2025(3)March 31, 2025(3)March 31, 2026March 31, 2025(3)Net income (loss) from continuing operations(27,566)6,317(12,128)(58,619)27,050Income tax expense (recovery)(538)973,2852,0954,245Other expense (income)1,6732,322(11,925)9,862(20,861)Share-based compensation689(551)3,7867,29312,930Depreciation and amortization3,8714,5833,37916,22815,430Business development costs8504436241,9753,435Inventory and biological assets fair value and
impairment adjustments20,4871,30621,95350,419(20,969)Business transformation costs (1)9,7613,8545,08224,55519,610Adjusted EBITDA (2)9,22718,37114,05653,80840,870(1)Business transformation related charges include costs related to closed facilities, certain IT project costs, sublease income, severance and retention costs in connection with the exit of the consumer market, legal provisions and costs associated with the retention of certain medical aggregators. (2)Adjusted EBITDA is defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.(3)Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs and non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation.Adjusted Net IncomeThe following is the Company's adjusted net income (loss):($ thousands)Three months endedYears endedMarch 31, 2026December 31, 2025March 31, 2025March 31, 2026March 31, 2025Net income (loss) from continuing operations(27,566)6,317(12,128)(58,619)27,050Inventory and biological assets fair value and
impairment adjustments20,4871,30621,95350,419(20,969)Business development costs8504436241,9753,435Impairment of property, plant and equipment2,2464—2,775(696)Impairment of intangible assets and goodwill———13,186—Deferred tax expense - impairment of intangible
assets and goodwill———5,856—Business transformation costs (1)9,5643,6414,82323,74618,401Adjusted net income (2)5,58111,71115,27239,33827,221(1)Business transformation costs  include certain IT project costs, severance and retention costs in connection with the exit of the consumer market, legal provision and costs associated with the retention of certain medical aggregators.(2)Adjusted net income is defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measuresAdjusted SG&AAdjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows:
Three months endedYears ended($ thousands)March 31, 2026December 31, 2025March 31, 2025March 31, 2026March 31, 2025General and administration29,54023,86125,078106,56791,323Sales and marketing16,02214,86015,40759,64156,170Business transformation costs (2)(5,308)(3,854)(5,082)(20,105)(19,610)Adjusted SG&A (1)40,25434,86735,403146,103127,883(1)Adjusted SG&A is defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.(2)Business transformation costs include certain IT project costs, severance and retention costs in connection with the business transformation plan and costs associated with the consumer channel exitFree Cash FlowThe table below outlines free cash flow for the periods ended:
Three months endedYears ended($ thousands)March 31, 2026December 31, 2025March 31, 2025March 31, 2026March 31, 2025Cash provided by (used in) operating activities
from continuing operations before changes in
non-cash working capital(9,410)9,517(2,969)1,3864,764Changes in non-cash working capital11,82310,5739,736(9,214)14,205Net cash provided by (used in) operating
activities from continuing operations2,41320,0906,767(7,828)18,969Less: maintenance capital expenditures(1)(2,097)(1,521)(1,518)(6,425)(8,084)Free cash flow(2)31618,5695,249(14,253)10,885(1)Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth.(2)Free cash flow is defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.Working CapitalWorking capital is a Non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as follows:($ thousands)Three months endedMarch 31, 2026December 31, 2025March 31, 2025Total current assets397,453445,836488,548Total current liabilities(66,930)(145,935)(149,807)Working capital330,523299,901338,741 View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-full-year-and-fiscal-2026-fourth-quarter-results-with-record-annual-revenue-and-adjusted-ebitda-302797627.htmlSOURCE Aurora Cannabis Inc. Original: Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹

Aurora Deepens its Impact for Veterans Across CanadaJune 2, 2026 7:07 AM
PR Newswire (Canada) NASDAQ | TSX: ACBFrom global leadership to local impact, Aurora continues to support Veteran-focused programs across Canada, addressing food security, mental health, and community engagementEDMONTON, AB, June 2, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, shares recent contributions through its Strains for Heroes program, expanding support for Veteran communities across Canada. Aurora's ongoing commitment to support Veterans includes five per cent of net profits from the sale of Strains for Heroes products being donated annually to veteran-focused organizations, up to a maximum of C$200,000. Aurora's latest contributions reflect a broader approach to care; supporting programs that address food security, mental health awareness, leadership development and community connection. "At a time when support matters most, we remain committed to showing up for Veterans in ways that matter," said Geoff Hoover, SVP, Commercial Canada at Aurora. "That starts with listening, understanding what Veterans need today, and engaging with them directly to support the work being done in Veteran communities across the country. As a medical cannabis company, we also have a responsibility to ensure our Veteran programs support the real experiences of Veteran patients. We're proud to stand alongside these organizations making a difference."Aurora's latest contributions support a range of Veteran-led organizations addressing real and immediate needs. Recent support includes a donation to the Veteran Association Food Bank to help distribute food assortments to Veteran families, as well as support for initiatives such as the Captain Nichola Goddard Fund which helps servicewomen, female Veterans, and their families access critical services. Donations were also made to national mental health awareness efforts like Sach in Motion and Sea to Sea for PTSD, where funds raised go towards treatment and education programs. Together, these contributions reflect Aurora's continued commitment to standing alongside Veterans and supporting the programs they rely on.Built in collaboration with Veteran patients, Strains for Heroes helps guide the development of select medical cannabis products. Launched in 2022, the program reflects the company's approach to giving back, supporting Veteran organizations through ongoing contributions that help sustain their essential services, strengthen their operations, and expand the support they're able to provide to Veterans and their families across Canada.Aurora is proud to support a growing number of veteran-focused organizations, by participating in community outreach, making charitable donations and amplifying their voices. Some partners include, Highway for Heroes, Quilts of Valour Canada, True Patriot Love, Fire Team K-9, and Veterans Association.For more information about the Strains for Heroes product offerings and Aurora's veteran program, visit AuroraMedical.com.About AuroraAurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.   Learn more at www.auroramj.com and follow us on X and LinkedIn.Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking Information  This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's ongoing contributions through its Strains for Heroes program, and associated impact including the expansion of support for veteran communities across Canada.These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-deepens-its-impact-for-veterans-across-canada-302787575.htmlSOURCE Aurora Cannabis Inc. Original: Aurora Deepens its Impact for Veterans Across Canada

Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End InformationMay 28, 2026 7:05 AM
PR Newswire (US) NASDAQ | TSX: ACBEDMONTON, AB, May 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2026 on Thursday, June 11, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter and fiscal year 2026 before the opening of markets that same day. Conference Call DetailsDATE:Thursday, June 11, 2026TIME:8:00 a.m. Eastern Time | 6:00 a.m. Mountain TimeWEBCAST:Click HereMiguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".About Aurora CannabisAurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.  Learn more at www.auroramj.com and follow us on X and LinkedIn.Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking StatementsThis news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing for the release of the Company's fourth quarter and fiscal year 2026 financial statements and the conference call to discuss the results.These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-to-host-fourth-quarter-and-fiscal-year-2026-investor-conference-call-and-file-related-year-end-information-302783891.htmlSOURCE Aurora Cannabis Inc. Original: Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End Information

Low Pole Reversal on 20 May 2026. BLTA
Supposed to be bullish. It is so with most stocks
Does not work with Aurora Cannabis Inc. It's a dead stock.

Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis ScienceMay 14, 2026 6:54 AM
PR Newswire (US) NASDAQ | TSX: ACBCanadian grant protects Aurora-developed genetics bred through the company's advanced research and breeding programEDMONTON, AB, May 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announced today it has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars developed through its world-class breeding program. This certification gives Aurora the exclusive rights to grow, propagate, and sell finished products produced from these varieties. The two protected cultivars, SOT20R07-007 (known as Farm Gas™) and SOT20R07-005 (known as Driftwood Diesel™), were developed at Aurora Coast, Aurora's industry-leading research and development facility in Comox, British Columbia. The company carefully selected these cultivars based on their unique characteristics, including how well they grow and how consistently they perform. Farm GasTM and Driftwood DieselTM are core medical cannabis products available to patients in Germany, Poland, UK, Canada, and Australia."These plant breeders' rights recognize the depth of work behind our leading breeding, genetic development and testing program," says Lana Culley, Vice President, Innovation and International Operations at Aurora. "They reflect a disciplined, science-driven approach to developing cultivars that deliver consistency, performance and reliability for medical cannabis patients around the world."Understanding Plant Breeders' Rights in CanadaPlant Breeders' Rights are a form of intellectual property protection, similar to patents, that apply specifically to new and distinct plant varietiesIn Canada, plant breeders' rights are granted by the Canadian Food Inspection Agency (CFIA) and give breeders exclusive rights to produce and sell a protected plant varietyThis framework recognizes the significant scientific investment required to develop cultivars that are clearly different and produce the same results over timeFor Aurora, plant breeders' rights protect proprietary cannabis genetics developed through its internal breeding program, supporting continued innovation and long-term researchAurora's robust genetics platform underpins its global medical cannabis leadership and supports the company's ability to develop differentiated premium products with consistent and reliable attributes. The protection of these varieties, as well as the recent grants received for select variety protection in Europe, enhances Aurora's competitive position globally.Further details regarding Plant Breeders' Rights, can be found at https://inspection.canada.ca/en/plant-health/plant-varieties/plant-breeders-rightsAbout AuroraAurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.Learn more at www.auroramj.com and follow us on X and LinkedIn.Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking InformationThis news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Plant Breeders' Rights granted by the CFIA to the Company in Canada and the associated benefits and advantages for the Company, as well as statements regarding the enhancement of Aurora's competitive position globally.These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-granted-plant-breeders-rights-strengthening-leadership-in-cannabis-science-302771046.htmlSOURCE Aurora Cannabis Inc. Original: Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science

Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International MarketsApril 28, 2026 6:53 AM
PR Newswire (US)

    NASDAQ | TSX: ACBQ1 launches reinforce Aurora's medical-first strategy, expanding access to high-quality products across multiple formatsScaled launches across Canada, Europe and Australia support growing demand in regulated international medical marketsContinued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP-certified networkEDMONTON, AB, April 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world. The newly expanded lineup includes dried flower, pre-rolls and pastilles, reflecting Aurora's long-standing focus on innovation, quality and patient choice, while driving sustainable growth internationally.







"As our global medical business continues to grow, our focus remains on delivering consistency and reliability across the markets we serve," says Lana Culley, VP Innovation & International Operations at Aurora. "By expanding our offerings in key countries, we're responding to clear patient and prescriber demand with products that meet local regulatory standards, offer meaningful choice across formats, and can be supplied reliably at scale - all while reinforcing the level of quality and trust expected from us."The new products align with Aurora's medical-first strategy and leverage the company's global GMP-certified manufacturing network.Aurora's expanded medical cannabis offerings will roll out in their respective markets between now and June; new product launches include:Germany – A broader portfolio of medical cannabis optionsSan Raf® – Pink OG KushTM | Indica, Dried Flower, THC 25-27%, CBD

Double Top Breakout on 22 Apr 2026. GLTA
The worst performing stock in my Port.

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - ACBApril 22, 2026 12:16 PM
PR Newswire (Canada)

TORONTO, le 22 avril 2026 /CNW/ - Reprise des négociations pour :Société : Aurora Cannabis Inc.Symbole TSX : ACBLes titres : NonReprise : 11 h 56:02 L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises

Original: L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - ACB

Canadian Investment Regulatory Organization Trading Halt - ACBApril 22, 2026 12:01 PM
PR Newswire (Canada)

TORONTO, April 22, 2026 /CNW/ - The following issues have been halted by CIRO:Company: Aurora Cannabis Inc.TSX Symbol: ACB All Issues: NoReason: Single Stock Circuit Breaker Halt Time (ET): 11:51:02CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Original: Canadian Investment Regulatory Organization Trading Halt - ACB

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - ACBApril 22, 2026 12:04 PM
PR Newswire (Canada)

TORONTO, le 22 avril 2026 /CNW/ - L'OCRI a suspendu la négociation des titres suivants :Société : Aurora Cannabis Inc.Symbole TSX : ACBLes titres : NonMotif : Coupe-circuits pour titre individuelHeure de la suspension (HE) : 11 h 51:02L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises

Original: Suspension de la négociation par l'Organisme canadien de réglementation des investissements - ACB

Canadian Investment Regulatory Organization Trade Resumption - ACBApril 22, 2026 12:12 PM
PR Newswire (Canada)

TORONTO, April 22, 2026 /CNW/ - Trading resumes in:Company: Aurora Cannabis Inc.TSX Symbol: ACB All Issues: NoResumption (ET): 11:56:02 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada..SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Original: Canadian Investment Regulatory Organization Trade Resumption - ACB

Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International MarketsApril 15, 2026 7:05 AM
PR Newswire (Canada)

NASDAQ | TSX: ACBEDMONTON, AB, April 15, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "Transaction").







"The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market. We intend to leverage our extensive plant science and operational expertise to increase the supply of high quality, EU GMP manufactured flower that further enhances our leadership in these expanding, high margin and highly regulated markets. An enhanced supply chain will enable us to capture greater international market share while delivering superior quality and value to our most respected patients worldwide," said Miguel Martin, Executive Chairman and Chief Executive Officer for Aurora.Strategic RationaleSafari Flower Company's 59,000 square foot, purpose-built EU GMP certified indoor cultivation and manufacturing facility in Ontario, Canada will provide the Company with incremental capacity that is closely aligned with its existing cultivation and manufacturing sites.The increased capacity will be used to supply EU GMP flower to Aurora's key international markets, including Germany, Australia, Poland, and the UK, and support further market expansion.This transaction is expected to deliver positive Adjusted EBITDA contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond as these assets are optimised within the Company's supply network.Aurora intends to leverage its plant science and operational expertise to realize operational efficiencies, improve cultivation yields and support commercial execution in the high margin international markets.Transaction DetailsAurora, through a wholly-owned subsidiary, indirectly purchased 100% of the shares of 9869247 Canada Limited ("Safari Flower Company") for aggregate consideration valued at $26.5 million, inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions. As consideration on closing, Aurora (i) issued the selling shareholder 2,417,180 common shares; and (ii) paid the selling shareholder $15 million in cash, subject to customary adjustments post-closing.About AuroraAurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.Learn more at www.auroramj.com and follow us on X and LinkedIn.Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking InformationThis news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the Transaction, including, but not limited to: the impact of the Transaction on the Company's financial performance and the synergies, revenue, positive cash flow and positive Adjusted EBITDA expected to be realized as a result of the Transaction.These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, current and expected market trends, product supply and demand, financial performance, and ongoing global regulatory developments, as well as publicly available information from governmental sources, market research and industry , and assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.Non-GAAP Measures
This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures in this news release include, but are not limited to, Adjusted EBITDA. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the Company's management's discussion and analysis for the three and nine months ended December 31, 3025, and 2025 (the "MD&A") is incorporated by reference into this news release. The MD&A is available on the Company's issuer profile on SEDAR+ at www.sedarplus.com.



View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-accelerates-global-medical-cannabis-leadership-with-accretive-acquisition-of-safari-flower-company-expanding-eu-gmp-capacity-to-serve-growing-high-margin-international-markets-302742337.htmlSOURCE Aurora Cannabis Inc.

Original: Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets

Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive YearMarch 30, 2026 7:03 AM
PR Newswire (Canada)

NASDAQ | TSX: ACBThe Globe and Mail's Report on Business Women Lead Here List acknowledges Aurora's commitment to inclusive leadership at the executive levelEDMONTON, AB, March 30, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has been named on The Globe and Mail's 2026 Report on Business Women Lead Here list for the second consecutive year. The annual editorial benchmark recognizes publicly traded Canadian companies demonstrating strong executive-level gender diversity, underscoring Aurora's continued commitment to inclusive leadership.







"This recognition reflects the culture we've built at Aurora - one grounded in respect, accountability, trust and our deliberate focus on developing a diverse pipeline of female talent," says Lori Schick, Executive Vice President, Human Resources at Aurora. "We've created an environment where female leaders thrive, drive meaningful results and move the business forward in a powerful way - making Aurora a destination for women who want to lead and make an impact."The Women Lead Here benchmark evaluates executive leadership teams at Canada's largest publicly traded companies using a proprietary, data-driven methodology that prioritizes measurable progress and sustained representation. Aurora is one of 85 companies to appear on this year's list with 50% female executive leadership.Aurora remains focused on fostering an environment where people are encouraged to contribute meaningfully, lead with compassion and succeed as a team. By fostering collaboration and welcoming diverse perspectives at every level of the organization, the company is enabled to create stronger outcomes for the patients and communities they serve.The 2026 Women Lead Here list is published in the April 2026 issue of Report on Business magazine, and is available online.About Aurora Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.Learn more at www.auroramj.com and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". About The Globe and MailThe Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.5million readers every week in our print or digital formats, and Report on Business magazine reaches 2.9million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.Forward Looking Information?? This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's ongoing commitment to inclusive leadership and focus on developing a diverse pipeline of female talent, as well as the associated positive impacts for the Company and its patients.These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.



View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-recognized-for-executive-gender-diversity-by-the-globe--mail-for-second-consecutive-year-302728026.htmlSOURCE Aurora Cannabis Inc.

Original: Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year

Low Pole Reversal on 04 March 2026. BLTA
"Horror-ah". The worst stock in my Port of about 6 dozen stocks!

Aurora to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 17, 2026 6:39 PM
PR Newswire (Canada)

NASDAQ | TSX: ACBCanada's Largest Global Medical Cannabis Company to Discuss Growth Strategy, Key Trends and Market OpportunitiesEDMONTON, AB, Feb. 17, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.







Conference DetailsDATE: Monday, March 2, 2026TIME: 11:10am Eastern Time | 9:10am Mountain TimeWEBCAST: Click HereThe fireside chat will be hosted by Derek Lessard, VP of Equity Research at TD Cowen. The discussion will explore Aurora's international leadership, shifts reshaping the global medical cannabis landscape, advancements in Canadian manufacturing excellence, and the broader market forces influencing the industry's growth.To listen to the live audio webcast, please register using the weblink above, which has also been posted to the Company's "Investor Info" section at https://www.auroramj.com/investors/ under "Events". A replay of the presentation will be available using the same link for approximately 90 days.Further, the Company announces that it has completed the transaction with Bevo Agtech Inc. ("Bevo"), previously announced on February 4, 2026 (the "Bevo Transaction"). Full details of the Bevo Transaction can be found in the February 4, 2026 press release located under the Company's profile at www.sedarplus.ca.About Aurora Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.Learn more at www.auroramj.com and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking InformationThis news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's upcoming participation at the TD Cowen 46th Annual Health Care Conference, as well as those related to the Company's global medical cannabis market leadership.These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.










View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-to-participate-in-the-td-cowen-46th-annual-health-care-conference-302691035.htmlSOURCE Aurora Cannabis Inc.

Original: Aurora to Participate in the TD Cowen 46th Annual Health Care Conference

Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical CannabisFebruary 12, 2026 4:05 PM
PR Newswire (US)

                                                                              NASDAQ | TSX: ACBEDMONTON, AB, Feb. 12, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the company will ring the Nasdaq closing bell on Wednesday, February 18, 2026, at the Nasdaq MarketSite in New York's Times Square.







The ceremony will be led by Aurora's CEO and Executive Chairman, Miguel Martin, alongside a representative of the company's Board of Directors, executive leadership team and other employees. This event celebrates Aurora's evolution into a medical-first, globally focused cannabis company and strengthened position in key international markets."As we advance our global medical strategy, this moment at Nasdaq underscores our longstanding commitment to serving patients worldwide," said Miguel Martin, CEO & Executive Chairman for Aurora. "Our medical business is the clear driver of Aurora's growth and today's milestone reflects the tremendous progress we've made in opening the world to cannabis, and the exciting opportunities still ahead."The Closing Bell ceremony will be broadcast live beginning at 3:45 p.m. ET, with the bell scheduled to ring at 4:00 p.m. ET, and streamed across Nasdaq's official channels. To view the live broadcast, visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.About Aurora Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.  Learn more at www.auroramj.com and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Information? This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's upcoming Nasdaq bell-ringing ceremony, the advancement of the Company's global medical cannabis strategy, the medical cannabis business as a driver of growth for the Company, and future growth opportunities. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.



View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-to-ring-the-nasdaq-closing-bell-on-wednesday-february-18-2026-reinforcing-strategic-focus-on-global-medical-cannabis-302686833.htmlSOURCE Aurora Cannabis Inc.

Original: Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis

Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New ZealandFebruary 11, 2026 7:00 AM
PR Newswire (US)

NASDAQ | TSX: ACBLaunch reinforces Aurora's leadership position across key international markets EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.







The expansion in New Zealand this month includes two new THC flower products – Big Wave™, Night Ride ™, as well as the balanced strain, Half Moon™ coming soon in Q1 FY27. The brand will also debut four new resin cartridges in Australia this month including, Chemango™ Kush, Cosmic Cream™, Lunar Express™, and Soul Train Haze™."With Australia being one of our largest international medical cannabis market, both Australia and New Zealand remain a top priority for Aurora, and we are deeply committed to our continued investment across the region," says Stanley Sack, Interim Managing Director of MedReleaf Australia. "As patient needs evolve, so does our responsibility to deliver high-quality, diversified product formats that support prescribers in delivering better care. Our focus on quality and reliable supply reflects our dedication to ensuring patients have meaningful access to the products they depend on."Each new product is derived from Aurora's proprietary genetics, and manufactured at the company's leading EU-GMP and TGA-GMP certified facilities in Canada, ensuring the highest standards of quality and safety.New Zealand Launches:Big Wave™ – Flower, Hybrid, THC 26%, CBD

Aurora Launches New European Websites, Showcasing Science-Backed Cannabis LeadershipFebruary 3, 2026 7:00 AM
PR Newswire (US)

NASDAQ | TSX: ACBLaunch of improved, localized websites underscores Aurora's long-term strategy for growth and engagement across key European medical marketsEDMONTON, AB, Feb. 3, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the launch of four brand new websites to support key European markets, continuing its investment in the region through a more focused, locally-relevant digital presence. The refreshed platforms are designed to better reflect Aurora's science-backed approach, manufacturing expertise, and brand strength, while improving engagement with healthcare professionals, partners, and prospective employees across Europe. The central European site, www.auroramedicine.com, provides easy access to the dedicated regional sites for Germany, the UK, and Poland.







"Our new European websites are a demonstration of our ongoing investment and long-term commitment to Aurora's fastest growing region," says Andreas Dotterweich, Senior Vice President, Aurora Europe. "The sites leverage our global leadership in medical cannabis, putting our products, scientific expertise and partnerships front and centre, providing enhanced resources for healthcare practitioners and partners looking for a trusted resource. This streamlined digital presence across Europe positions Aurora to drive growth, reinforce our leadership, and deliver lasting value in Europe."Building on the recent evolution of Aurora's global brand identity, the new regional websites showcase manufacturing excellence, highlighting both Canadian-made and local production through updated videos and photos while emphasizing quality, compliance, and evidence-based processes. Each platform is available in the native language of its market, and all regional sites are seamlessly accessible from the drop-down menu on the central European hub.The new websites enhance the experience for healthcare practitioners and partners across Europe. Aligned with Aurora's broader European communications strategy, they establish a locally relevant platform that strengthens engagement, showcases the company's leadership, and positions Aurora to capture emerging opportunities in the evolving medical cannabis market.About AuroraAurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's™ and Whistler Cannabis Co™. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.Learn more at www.auroramj.com and follow us on X and LinkedIn.Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".Forward Looking Information  This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of the Company's new European-based websites and associated benefits, including to drive growth, reinforce the Company's leadership, and deliver lasting value in Europe; the Company's long-term strategy for growth and engagement across key European medical markets; and the Company's global leadership in medical cannabis and ability to capture emerging opportunities.These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.



View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-launches-new-european-websites-showcasing-science-backed-cannabis-leadership-302676808.htmlSOURCE Aurora Cannabis Inc.

Original: Aurora Launches New European Websites, Showcasing Science-Backed Cannabis Leadership

$7s next 

)5.38

Get high now 

that was underwhelming A.F. !

earnings reported in the a.m. I expect positive results . calls on the launch pad .

https://app.aistudios.com/share/68f7ec56612d3d2b7234d4af Bullish!!

Double Top Breakout on 7-Oct-2025. GLTA...Surprise!
Crossing my fingahs!

Just a glimmer of hope, may be.
"Horror-ah" Cannabis share price did have a Bullish Triangle Breakout on 13-Aug-2025
How the hell did I miss that?
Simple, 'cause I've had it enough... and stopped even checking its chart.
The worst company in among about 4 dozen stocks in my Port.
Now I'm "billush" about it!

Long Tail Up on 29-Sep-2025.
Another unreliable price jump of this what comes across of a sham of a company, imo

absolutely !!! thats an awesome post BTW !!!

A hopeless of a case of Aurora Can....

Supreme Court has gone rogue. The constitution is just an annoyance to them now it seems. Nothing they do or say should be considered as law anymore. They proved they are a complete fraud during covid when the refused to rule on a covid case based possible ",chaos". What? That is not how they are supposed to operate. They are supposed to uphold the Constitution. Maybe there needed to be mass chaos

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176001986 $ACB

MACD about to cross down. Probably going to drop with no sector news... 

$6.40 Kennedy he also endorsed federal rescheduling and allowing marijuana businesses to access the banking system.
, Robert F. Kennedy Jr., had advocated for legalizing marijuana, as well as psychedelics for the treatment of serious mental health conditionsCGC tomorrow earnings see $3s should have similar results as ACB 
$CGC 5,118,426 Shares (the “TRA Shares”) issued on December 9, 2024 pursuant to the Third Amendment to Tax Receivable Agreement (the “TRA Amendment”), dated as of October 24, 2022, by and among us, Canopy USA, LLC, a Delaware limited liability company (“Canopy USA”), Acreage Holdings America, Inc., a Nevada Corporation, High Street Capital Partners, LLC, a Delaware limited liability company (“HSCP”), and certain members of HSCP. 
(ii)1,315,553 Shares (the “Put Shares”) and 1,197,658 Shares (the “Put Warrant Shares”) issuable upon the exercise of warrants (the “Put Warrants”), issued on December 9, 2024, to satisfy an outstanding put liability that was assigned to us. Each Put Warrant is exercisable for one common share at an exercise price of US$3.66 per share, and is exercisable for a period that commenced on December 9, 2024 and will end on June 6, 2029.A lobbying contribution report filed with Congress shows that the multi-state cannabis operator Curaleaf, via the U.S. Cannabis Council (USCC), contributed a quarter million dollars to the president following his election victory last November.
“I was proud to stand alongside cannabis industry leaders at President Trump’s inauguration,” David Culver, senior vice president of public affairs at USCC, told Marijuana Moment.
“We face a wide range of challenges—including addressing debanking and finishing rescheduling—that our leaders in Washington can address,” he said. “President Trump has embraced federal cannabis reform and voiced support for the right of states to set their own cannabis laws. We look forward to working with him and his administration to meaningfully move cannabis policy forward.”
NOTUSMeanwhile, another top marijuana executive—Trulieve CEO Kim Rivers—has also been making inroads within Trump circles.
Not only did she meet with the then-candidate last year prior to his endorsement of a Florida cannabis legalization ballot initiative that Rivers’s company largely funded, but she also attended two pre-inauguration events: a dinner celebrating Vice President J.D. Vance and a separate candlelight dinner On the campaign trail after meeting with Rivers, he also endorsed federal rescheduling and allowing marijuana businesses to access the banking system.vices (HHS), Robert F. Kennedy Jr., had advocated for legalizing marijuana, as well as psychedelics for the treatment of serious mental health conditions

$4.83 + 31% How you like  it now cash positive earnings 

ABC time bottom in ? $3.80s Not much changing with Trump which is ok and a bonus would be financial status that gets a real rally going. 

Wow look at this POS tank. Will be funny if trump signs an executive order next week to legalize federally. Any thing is possible. The stock is so low now it's a great opportunity for congressional insider trading

Badog, now I'm beginning to understand why you post so much on ERHC ... Cannibis... 😁

Will be interesting tomorrow. Wonder why this couldn't hold gains again?

Strange trading on this one yesterday. A lot of movement both ways. Maybe something is brewing. January effect?

They are trying to drop the price so they can load up before new legislation comes out to legalize or they at least lie about new legislation to pump the stocks. There arebt a lot of bargains out there right now in other sectors. Perfect time to pump this for the pelosia of the world

I would definitely qualify myself

Thanks ! Tomorrow I will call my brokerage and find out when, how much and cost of the shares I bought and sold. Can't just go into my account and look because records only go back two years. I still do not know if this lawsuit settlement will be worth my time.

First I heard of it. I'll have to check into it

What's going on with this postcard about litigation? I can't even get my records going back that far to find out how many shares I bought and sold. Anyone know if it is worth asking my broker and wasting time only to get 30 cents form the settlement?

Does this stock suck or what? Can't even hold a .05 gain for more than a few minutes

republican government actually support mj even the president said it himself. Again i can wait it out while playing cryptos and other stocks i got time to make the trade.

double post

Unfortunately I have to go where the trend is now. I don't have money to hold long term. Made bank in qub# and xrp. This is getting worse by the day. Their is no hope left for these companies now that Republicans will control the US Government.